Cancer Drugs Remain Hot Targets.
Estimates of future growth in the oncology market, a predicted increase of 11% per year in sales, and the need to expand drug-development pipelines to sustain profits have been driving up the value of corporate mergers, such as Pfizer's purchase of Medivation for $14 billion.